Eric W. Hoffman

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Andrew M. Scott, G. Wiseman, Sydney Welt et al. · PubMed · 2003 · 441 citations

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

Ian D. Davis, Weisan Chen, Heather Jackson et al. · Proceedings of the National Academy of Sciences · 2004 · 437 citations · Full text

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers

Elke Jäger, Sacha Gnjatic, Yasuhiro Nagata et al. · Proceedings of the National Academy of Sciences · 2000 · 426 citations

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

Paul Sabbatini, Takemasa Tsuji, Luis Ferran et al. · Clinical Cancer Research · 2012 · 272 citations

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

Kunle Odunsi, Feng Qian, Junko Matsuzaki et al. · Proceedings of the National Academy of Sciences · 2007 · 266 citations · Full text

Histocompatibility, Cancer Vaccine Design, Immunology +21